The report involved motor neuropathy in a participant of the phase 2 trial conducted outside the U.S., according to an Oct. 16 news release from the company. The participant received the vaccine in January 2023 and reported the serious adverse event in September 2024, after the trial was concluded in July 2023.
Novavax Chief Medical Officer Robert Walker, MD, emphasized the company’s commitment to safety, stating, “While we do not believe causality has been established for this serious adverse event, we are committed to working expeditiously with the FDA to resolve this matter.”
Data from previous trials has not indicated any signals for motor neuropathy, and investigators have been notified about the clinical hold, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
